-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 T/bqHR1ngzqANKljKg0jddCp+T6mWuf7WCXfSRYJBapuKgrGTO6obPknOvCMTvdP
 M7sgWtyus/kslPVgnOB3Pg==

<SEC-DOCUMENT>0000950144-07-008905.txt : 20070928
<SEC-HEADER>0000950144-07-008905.hdr.sgml : 20070928
<ACCEPTANCE-DATETIME>20070928083141
ACCESSION NUMBER:		0000950144-07-008905
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20070926
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070928
DATE AS OF CHANGE:		20070928

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	COMPUTER & OFFICE EQUIPMENT [3570]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		071140659

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g09705e8vk.htm
<DESCRIPTION>GEOVAX LABS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>GEOVAX LABS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>&nbsp;<BR>
FORM 8-K</B>
</DIV>

&nbsp;



<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV><BR>
&nbsp;</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0%"><B><B>Date of report (Date of earliest event reported): September&nbsp;26, 2007</B>
</B>
</DIV>

&nbsp;


<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in Charter)</B></DIV>



&nbsp;


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Illinois<BR>
(State or other jurisdiction of <BR>
incorporation or organization)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091<BR>
(Commission File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038<BR>
(IRS Employee Identification No.)</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1256 Briarcliff Road N.E.<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306<BR>
(Address of Principal Executive Offices)</B></DIV>

&nbsp;


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(404)&nbsp;727-0971<BR>
(Issuer Telephone number)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the Registrant under any of the following provisions (see General Instruction
A.2 below).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4<SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> under the Exchange Act (17 CFR
240.13(e)-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time to
time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 Other Events</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;26, 2007 we issued a press release announcing the receipt of an estimated $15
million federal grant in support of our HIV/AIDS vaccine program. A copy of the press release is
attached to this Current Report.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;24, 2007 we issued a press release commenting on the discontinuance of an HIV
clinical trial by Merck &#038; Co., Inc. A copy of the press release is attached to this Current
Report.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;12, 2007 we issued a press release announcing the presentation of our HIV/AIDS
clinical trial data at the AIDS Vaccine 2007 Conference. A copy of the press release is attached
to this Current Report.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">Exhibit&nbsp;99.1 Press Release<BR>
Exhibit&nbsp;99.2 Press Release<BR>
Exhibit&nbsp;99.3 Press Release
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: September&nbsp;28, 2007
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>g09705exv99w1.htm
<DESCRIPTION>EX-99.1 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.1 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;99.1
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>AT THE COMPANY</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="3" style="border-bottom: 1px solid #000000"><B>AT FINANCIAL RELATIONS BOARD</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Don Hildebrand
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tim Grace
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phil Nourie</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">or
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Media Contact
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Media Contact</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jennifer Nelms
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">312-640-6667
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">212-827-3760</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(404) 727-0971</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>U.S. GOVERNMENT AWARDS $15 MILLION GRANT TO<BR>
GEOVAX LABS&#146; HIV/AIDS VACCINE PROGRAM</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>ATLANTA, Ga., 26 Sept 2007 &#150; GeoVax Labs, Inc. (OTC BB: GOVX)</B>, an Atlanta based biotechnology
company, announced receipt of an estimated $15,000,000 Integrated Preclinical/Clinical AIDS Vaccine
Development &#091;IPCAVD&#093; Grant to support its HIV/AIDS vaccine program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This large Grant was awarded by the National Institutes of Health-National Institute of Allergy &#038;
Infectious Disease &#091;NIH-NIAID&#093;, an agency of the U.S. Government. Funding commences October&nbsp;2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Only meritorious HIV/AIDS prevention vaccine candidates are considered to receive an IPCAVD award.
Candidate companies are highly scrutinized and must supply substantial positive AIDS vaccine data
to support their application. IPCAVD grants are awarded on a competitive basis and are designed to
support later stage vaccine research, development and human trials.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax will utilize this funding to further its HIV/AIDS vaccine development, optimization,
production and human clinical trial testing including Phase 2 human clinical trials planned for
2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dr.&nbsp;Harriet Robinson, Chief Scientific Advisor for GeoVax, guided development of the IPCAVD
proposal and will lead a major part of its related studies. Dr.&nbsp;Robinson stated, &#147;This grant will
allow GeoVax to move forward our AIDS vaccine evaluation program more efficiently and more
rapidly.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;Our selection as a grant recipient is a validation of our vaccine technology, scientific program,
success in human trials to date and future strategies,&#148; said GeoVax President/CEO, Don Hildebrand.
&#147;This $15&nbsp;million in funding will support additional AIDS vaccine studies as well as expansion of
our scientific team at GeoVax.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">* * * * * * * * * * * * * * *<BR>
About GeoVax Labs, Inc. (www.geovax.com)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and
commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other
infectious agents. GeoVax&#146;s vaccine technology is protected by 20 filed patent applications and
issued patents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease
(AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the
AIDS virus. In addition, GeoVax AIDS vaccines may be effective as therapeutics (treatment of
people infected with AIDS virus). Studies evaluating these vaccines in already HIV/AIDS infected
individuals are being planned.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">GeoVax DNA and Recombinant MVA HIV/AIDS vaccines:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#151; Use DNA vaccines to &#147;prime&#148; immune responses and MVA vaccines to &#147;boost&#148; immune responses against the AIDS virus

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#151; Vaccinate against more than 50% of AIDS virus components and can not cause AIDS<BR>
&#151; Protected 22 of 23 (96%) non-human primates for over 3 <FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT> years post-infection with an AIDS inducing virus. Five of six non-vaccinated controls died of AIDS within the 1st year of infection.
These trials used a prototype SIV/HIV vaccine for the HIV vaccine that is being advanced in human trials
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">&#151; Are manufactured &#038; tested under GMP/GLP &#150; EMEA (EU)&nbsp;and FDA guidelines<BR>
&#151; Satisfactorily completed earlier DNA HIV/AIDS vaccine Phase 1 human trial<BR>
&#151; Are currently being tested in 4 Human Trials. Two started in 2006, two in summer 2007<BR>
&#151; Have been demonstrated safe to date in human trials<BR>
&#151; Are demonstrating positive immune responses against HIV in majority of vaccine recipients<BR>
&#151; Are in planning stage for a larger Phase 2 human trial in 2008

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For further information, contact Don Hildebrand or Jennifer Nelms at (404)&nbsp;727-0971 or visit
www.geovax.com.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Safe Harbor Statement: All statements in this news release, not statements of historical fact, are
forward-looking statements. These statements are based on expectations and assumptions as of the
date of this press release and are subject to numerous risks and uncertainties which could cause
actual results to differ materially from those described in the forward-looking statements. Risks
and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture
these vaccines with the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be
determined to be safe for use in humans, GeoVax&#146;s vaccines will be effective in preventing AIDS in
humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed,
GeoVax can raise the required capital to complete development of its vaccines, there is development
of competitive products that may be more effective or easier to use than GeoVax&#146;s products, and
other factors over which GeoVax has no control. GeoVax assumes no obligation to update these
forward-looking statements, and does not intend to do so. Certain matters discussed in this news
release are forward-looking statements involving certain risks and uncertainties including, without
limitations, risks detailed in the Company&#146;s Securities and Exchange Commission filings and report.</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>g09705exv99w2.htm
<DESCRIPTION>EX-99.2 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.2 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;99.2
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>AT THE COMPANY</B></U><BR>
Don Hildebrand<BR>
or<BR>
Jennifer Nelms<BR>
(404)&nbsp;727-0971

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC. COMMENTS ON<BR>
DISCONTINUANCE OF MERCK&#146;S HIV VACCINE TRIAL</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ATLANTA &#150; September&nbsp;24/PRNewswire First Call/ &#151; GeoVax Labs, Inc. (OTC:BB GOVX)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On September&nbsp;21, 2007, Merck &#038; Co., Inc. announced their candidate AIDS vaccine failed to provide
protection in a human study designed to test for efficacy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In this Merck trial involving high risk volunteers, an equal number of people received either
placebo or AIDS vaccine. The independent Data Safety Monitoring Board recommended that the trial be
stopped because it was not reaching its efficacy endpoints.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Merck has stopped further vaccinations but will continue to follow volunteers in the trial. The
Merck trial was being carried out in conjunction with the HIV Vaccine Trials Network (HVTN), a
prestigious trial network funded by the US National Institutes of Health.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Don Hildebrand, GeoVax&#146;s President and CEO, commented, &#147;We, along with the rest of the scientific
community, are disappointed in the clinical failure of Merck&#146;s HIV vaccine trial. We all share the
same goal of finding a safe and effective vaccine to address the devastation of the HIV/AIDS
epidemic. We, however, would like to take this opportunity to highlight important differences
between our vaccine technology and the technology used in the Merck trial.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax AIDS vaccines advancing in human trials represent a significantly different vaccine
approach, vaccine composition and results to date than the Merck vaccine.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1) Prototypes for the GeoVax vaccines were selected from a series of trials in non-human primates
for their ability to protect against the development of AIDS when vaccinated individuals were
administered an AIDS causing virus. At each major step along the development pathway, GeoVax
vaccines providing the best protection against AIDS were moved forward.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2) GeoVax AIDS vaccines demonstrated excellent protective results in non-human primate models, much
better protective results than reported for Merck&#146;s vaccine in similar models. GeoVax AIDS
vaccines protected 22/23 non-human primates for over 3 <FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT> years and 5/6 non-vaccinated controls died
of AIDS post-AIDS virus infection.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3) GeoVax AIDS vaccines are designed to elicit protective antibodies (Ab) as well as protective T
cells (white blood cells) against the AIDS virus. The Merck vaccine stimulates only T cells for
providing protection and does not include the Env protein of HIV which is the target for protective
antibody (Ab).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4) Protective Ab has been difficult to elicit with HIV/AIDS vaccines. GeoVax has approached this
challenge by vaccinating with the natural form of Env (HIV envelope antigens) under conditions that
elicit tightly binding Ab. GeoVax studies in non-human primates clearly show this Ab correlates
with protection.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5) GeoVax vaccines use an attenuated smallpox vaccine to provide pulses of HIV proteins (antigen)
to stimulate protective anti-AIDS vaccine responses. Pulses of antigen from the GeoVax vaccines
elicit T cell responses that rapidly mobilize and then contract into a state called &#147;central
memory&#148; from which they rapidly expand to fight the appearance of HIV.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Merck&#146;s vaccines use adenovirus instead of poxvirus vectors. Adenovirus vectors provide more
prolonged AIDS virus antigen exposure than the GeoVax poxvirus vectors. Prolonged antigen exposure
affects the state of elicited T cells and can compromise the ability to rapidly expand in the fight
against an infection.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;The Merck study highlights the importance of clinical trials in vaccine development,&#148; said Dr.
Harriet Robinson, Chief Scientific Advisor for GeoVax. &#147;The volunteers who participate in these
trials are Heroes of Vaccine Development and make it possible for products that are safe and
effective to be identified and licensed for human use. GeoVax salutes the volunteers who
participated in the Merck trials and the volunteers that are participating in the GeoVax trials.
These are people who care and have volunteered for the greater good of humanity.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax AIDS vaccines are being prepared to enter Phase 2 human trials. These large trials will
expand the safety and positive immune response data demonstrated in the five (5)&nbsp;prior GeoVax AIDS
vaccine trial groups. These trials will be conducted in collaboration with the HIV Vaccine Trials
Network.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On the basis of non-human primate studies, GeoVax believes its vaccines will be safe and
protective. A rigorously conducted clinical trial in human volunteers will be accomplished to
confirm effectiveness in preventing AIDS. With 14,000 new HIV/AIDS infections reported daily and
more than 60&nbsp;million people living with HIV/AIDS worldwide, the need for an effective HIV/AIDS
vaccine is extremely urgent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Note: The US Food and Drug Administration (FDA)&nbsp;has established and oversees the regulatory
guidelines for clinical trials in the United States and requires regular reports on the progress of
clinical trials. The HIV Vaccine Trials Network provides a unifying structure for trials of
candidate HIV/AIDS vaccines.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">* * * * * * * * * * * * * * *
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">About GeoVax Labs, Inc. (www.geovax.com)

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and
commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other
infectious agents. GeoVax&#146;s vaccine technology is protected by 20 filed patent applications and
issued patents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease
(AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to their infection
with the AIDS virus. GeoVax vaccine regimens employ a &#147;prime-boost&#148; strategy where its DNA vaccine
&#147;primes&#148; the immune response and is followed by administration of the GeoVax MVA (Modified Vaccinia
Virus) booster vaccination. Both vaccines deliver over 50% of the AIDS virus components but cannot
cause AIDS. In addition, GeoVax AIDS vaccines may be effective as therapeutics &#091;AIDS treatments&#093;.
Studies evaluating these vaccines in already HIV/AIDS infected individuals are being planned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax DNA and Recombinant MVA HIV/AIDS vaccines:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#151; Use DNA for priming vaccine responses and recombinant MVA to boost vaccine responses (DNA/MVA
vaccine)
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#151; Protected 22 of 23 (96%) non-human primates for over 3 <FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT> years post-infection with an AIDS
causing virus. Five of six non-vaccinated controls died of AIDS within the 1st year of infection.
These trials used a prototype SIV/HIV vaccine for the HIV vaccine that is being advanced in human
trials
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">&#151; Are manufactured &#038; tested under GMP/GLP &#150; EMEA (EU)&nbsp;and FDA guidelines
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">&#151; Satisfactorily completed earlier DNA HIV/AIDS vaccine Phase 1 human trial
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">&#151; Are currently being tested in 4 Human Trials. Two started in 2006, two in mid-07.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">&#151; Have been safe in all tested humans
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">&#151; Are demonstrating positive immune responses in the majority of vaccine recipients
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">&#151; Are in planning stage for a larger Phase 2 human trial in 2008
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For further information, contact Don Hildebrand or Jennifer Nelms at (404)&nbsp;727-0971 or visit
www.geovax.com.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Safe Harbor Statement: All statements in this news release, not statements of historical fact, are
forward-looking statements. These statements are based on expectations and assumptions as of the
date of this press release and are subject to numerous risks and uncertainties which could cause
actual results to differ materially from those described in the forward-looking statements. Risks
and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture
these vaccines with the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be
determined to be safe for use in humans, GeoVax&#146;s vaccines will be effective in preventing AIDS in
humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed,
GeoVax can raise the required capital to complete development of its vaccines, there is development
of competitive products that may be more effective or easier to use than GeoVax&#146;s products, and
other factors over which GeoVax has no control. GeoVax assumes no obligation to update these
forward-looking statements, and does not intend to do so. Certain matters discussed in this news
release are forward-looking statements involving certain risks and uncertainties including, without
limitations, risks detailed in the Company&#146;s Securities and Exchange Commission filings and report.</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>g09705exv99w3.htm
<DESCRIPTION>EX-99.3 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.3 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;99.3
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>AT THE COMPANY</B></U><BR>
Don Hildebrand<BR>
or<BR>
Jennifer Nelms<BR>
(404)&nbsp;727-0971

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX SUCCESFUL HIV/AIDS VACCINE TRIAL DATA<BR>
PRESENTED AT AIDS VACCINE 2007 CONFERENCE</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>ATLANTA &#150; September&nbsp;12/PRNewswire First Call/ &#151; GeoVax Labs, Inc. (OTC:BB GOVX), </B>an Atlanta based
biotechnology company, announced the presentation of successful human trial results for its
HIV/AIDS vaccines at the AIDS Vaccine 2007 Conference held August&nbsp;20-23, 2007 in Seattle,
Washington.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax HIV/AIDS human trial results were presented by Dr.&nbsp;Paul Goepfert, MD in a talk &#147;HIV-1 DNA
Prime followed by Recombinant MVA Boost is Well Tolerated and Immunogenic When Administered to
Healthy Seronegative Adults.&#148; Dr.&nbsp;Goepfert, from the University of Alabama-Birmingham, is Protocol
Chair of HVTN 065, a series of human clinical trials currently evaluating GeoVax&#146;s HIV/AIDS
vaccine.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax HIV/AIDS vaccine trial data was presented to over 900 AIDS researchers at the week long
conference. Conference Chair, Dr.&nbsp;Lawrence Corey stated, &#147;It has become clear that a preventative
vaccine is essential to controlling the global AIDS epidemic.&#148; The AIDS Vaccine 2007 Conference was
organized under the guidance of the Global HIV Vaccine Enterprise, an alliance of independent
global organizations dedicated to accelerating preventative AIDS vaccine development.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The conference reported the AIDS epidemic continuing as a global threat with the disease increasing
in every region of the world, especially East and Central Asia and Eastern Europe where AIDS
incidence was 21% higher in 2006 than in 2004.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Key GeoVax HIV/AIDS Vaccine Human Trial conclusions presented at the AIDS Vaccine 2007 Conference
included:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>-</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GeoVax DNA and MVA vaccines are <I>safe and immunogenic </I>(stimulate anti-HIV/AIDS immune
responses) at both low (1/10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) dose and full doses.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>-</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GeoVax vaccines were <I>well tolerated </I>with no or mild local and systemic reactions in the
majority of trial participants.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>-</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>80% of both the low and full dose trial participants responded to the vaccine which
<I>stimulated highly desirable anti-HIV T-cell (white blood cell) and antibody responses</I>.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>-</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>More volunteers had antibody responses </I>to the full dose than to the 1/10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> dose
vaccine, whereas response rates for T cells were similar for the 1/10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> and full
dose.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>-</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> MVA vaccination <I>positively increased the number of CD8 T cell responders and
antibody responders.</I></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>-</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Excellent results </I>led to authorization to start two new trials with GeoVax HIV/AIDS
vaccines which began in June&nbsp;2007.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">These human trials, utilizing GeoVax&#146;s HIV/AIDS vaccines, are conducted by the HIV Vaccine Trials
Network (HVTN)&nbsp;based in Seattle, Washington. The HVTN, funded and supported by the National
Institutes of Health (NIH), is the largest worldwide clinical trials program devoted to the
development and testing of HIV/AIDS vaccines. Preclinical work enabling development of the clinical
evaluation of
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax&#146;s DNA and MVA vaccines was also funded and supported by the NIH National Institute of
Allergy and Infectious Diseases (NIAID).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">* * * * * * * * * * * * * * *
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">About GeoVax Labs, Inc. <I>(www.geovax.com)</I>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, manufacture,
license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency
Virus) and other infectious agents. GeoVax&#146;s vaccine technology is protected by 20 issued and
filed patent applications.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">GeoVax&#146;s DNA and Recombinant MVA HIV/AIDS vaccines:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Uses DNA for priming the vaccine responses and recombinant MVA to boost the vaccine
response (DNA/MVA vaccine)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Protected 22 of 23 (96%) non-human primates for over 3<FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT> years post-infection with an AIDS
causing virus &#150; 5 of 6 non-vaccinated controls died of AIDS within the 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> year of
infection. These trials used a prototype SIV/HIV vaccine for the HIV vaccine that is being
advanced in human trials</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Are manufactured and tested under GMP/GLP &#150; EMEA (EU)&nbsp;and FDA guidelines</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Satisfactorily completed early Phase 1 human clinical trials for a DNA HIV/AIDS vaccine</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Are currently in 4 ongoing human trials started in 2006 with positive immune responses
reported in the majority of vaccine recipients as well as good vaccine safety</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Are in planning stage for a larger Phase 2 trial tentatively scheduled for 2008</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For further information, contact Donald Hildebrand or Jennifer Nelms at (404)&nbsp;727-0971 or visit
www.geovax.com.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Safe Harbor Statement: All statements in this news release, not statements of historical fact, are
forward-looking statements. These statements are based on expectations and assumptions as of the
date of this press release and are subject to numerous risks and uncertainties which could cause
actual results to differ materially from those described in the forward-looking statements. Risks
and uncertainties include, but are not limited to, whether; GeoVax can develop and manufacture
these vaccines with the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be
determined to be safe for use in humans, GeoVax&#146;s vaccines will be effective in preventing AIDS in
humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed,
GeoVax can raise the required capital to complete development of its vaccines, there is development
of competitive products that may be more effective or easier to use than GeoVax&#146;s products, and
other factors over which GeoVax has no control. GeoVax assumes no obligation to update these
forward-looking statements, and does not intend to do so. Certain matters discussed in this news
release are forward- looking statements involving certain risks and uncertainties including,
without limitations, risks detailed in the Company&#146;s Securities and Exchange Commission filings and
report</I>.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
